scorecardresearchSolara Active Pharma Sciences Share Price 341.05

Solara Active Pharma Sciences

BSE: 541540 | NSE: SOLARA | ISIN: INE624Z01016 | SECTOR: Biotechnology & Drugs

341.05 0.00 (0%)

05 Jul 2022, 09:58 (IST)
  • Open

    348.00
  • High

    352.40
  • Low

    341.05
  • Prev Close

    345.75
  • P/E

    -
  • Median P/E

    -
  • P/B

    -
  • Median P/B

    -
  • Market Cap

    -
  • Volume

    3.33K
  • Vol. (20 day Avg.)

    0
  • PEG

    -
  • Div.Yield

    -
  • Bid

    -
  • Ask

    343.30
  • 341.05
  • Intraday
  • 352.40
  • 323.65
  • 52 Wk H/L
  • 1,830.00
  • 276.60
  • DPR
  • 414.90

Key Metrics

- Mkt. Cap.

V

Volatility %

B

Beta -

Genie Says

Financials

  • Actuals
  • Forecasted

Revenue vs. Profit Trend

No Chart data available

Peer Comparison

  • Price Comparison
  • Ratios Comparison
No data available
CompanyLatest Price
Change (% Chg)
52 Week
High
52 Week
Low
Market Cap.
(Cr)

Events

  • Dividends
  • Bonus
  • Splits
  • Rights
  • Board Meetings
  • Annual General Meetings

Ex-Dividend

Div Value

Description

    Simple Moving Averages

    DaysBSENSE

    Solara Active Pharma Sciences is trading higher than 5 day, 20 day, 100 day and 200 day moving averages.

    Company Description

    • Large Cap
    • Automobiles
    • BSE

      541540
    • NSE

      SOLARA
    • ISIN

      INE624Z01016

    Solara Active Pharma Sciences Limited is an India-based company, which is engaged in the business of manufacturing and development of active pharmaceutical ingredients (API). The Company is involved in contract manufacturing and development services for global companies. Its commercial products include Aprepitant (Antiemetic), Brivaracetam (Antiepileptic), Bumetanide (Inj) (Loop Diuretic), Buspirone Hcl (Anxiolytic), Cevimeline Hydrochloride (Muscarinic Agonist), Cinacalcet Hydrochloride (Calcimimetic Agent), Citicoline Sodium (Anticonvulsant), Colchicine (Antigout Agent), Disulfiram (Chronic Alcoholism), Edaravone (Recovery Of Stroke), Etomidate (Anesthetics), Felbamate (Anticonvulsant), Flecainide Acetate (Anti-Arrhythmic Agent), Rifaximin (Antibiotic), S-Ibuprofen (Anti-Inflammatory), Oseltamivir Phosphate(Antiviral) and Levetiracetam (Anticonvulsant). It provides services, such as synthetic development, analytical development, process engineering, and regulatory services.

    Company Officers

    • Subramanian Hariharan

      Chief Financial Officer, Executive Director
    • Sudhir Nambiar

      Chief Scientific Officer (Head R&D)
    • S. Murali Krishna

      Compliance Officer, Company Secretary
    • Jitesh Devendra

      Managing Director
    • V. Sundara Moorthy

      Chief Quality Officer